Allele frequencies in the group of 110 patients and in a healthy white population
.  | Patients .  | . | . | White population* .  | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genes .  | A, % .  | B, % .  | C, % .  | A, % .  | B, % .  | C, % .  | ||||
| MDR1 (1) | 73 | 26 | 1 | 74 | 24.04 | 1.96 | ||||
| MDR1 (2) | 31 | 50 | 19 | 41.4 | 45.9 | 12.6 | ||||
| TOP2A | 62 | 32 | 6 | 52.5 | 39.9 | 7.5 | ||||
| SXR (1) | 43 | 44 | 13 | 36 | 48 | 16 | ||||
| SXR (2) | 42 | 44 | 14 | 47.8 | 42.7 | 9.5 | ||||
| GSTT1 | 87 | 7 | 6 | 53.6 | 39.2 | 7.2 | ||||
| SULT1C2 | 50 | 39 | 11 | 65.3 | 31 | 3.7 | ||||
| VEGF (1) | 19 | 61 | 20 | 38.8 | 47 | 14.2 | ||||
| VEGF (2) | 46 | 40 | 14 | 49 | 42 | 9 | ||||
| XPD | 44 | 46 | 10 | 34.8 | 48.4 | 16.8 | ||||
| XPA | 48.3 | 40.5 | 11.1 | 38.8 | 47 | 14.2 | ||||
| ERCC1 | 72 | 25 | 3 | 59.4 | 35.4 | 5.2 | ||||
| ERCC5 | 32 | 45 | 23 | 29.2 | 49.7 | 21.2 | ||||
| CDA |  49.5  |  39.4  |  11.1  |  —  |  —  |  —  | ||||
.  | Patients .  | . | . | White population* .  | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genes .  | A, % .  | B, % .  | C, % .  | A, % .  | B, % .  | C, % .  | ||||
| MDR1 (1) | 73 | 26 | 1 | 74 | 24.04 | 1.96 | ||||
| MDR1 (2) | 31 | 50 | 19 | 41.4 | 45.9 | 12.6 | ||||
| TOP2A | 62 | 32 | 6 | 52.5 | 39.9 | 7.5 | ||||
| SXR (1) | 43 | 44 | 13 | 36 | 48 | 16 | ||||
| SXR (2) | 42 | 44 | 14 | 47.8 | 42.7 | 9.5 | ||||
| GSTT1 | 87 | 7 | 6 | 53.6 | 39.2 | 7.2 | ||||
| SULT1C2 | 50 | 39 | 11 | 65.3 | 31 | 3.7 | ||||
| VEGF (1) | 19 | 61 | 20 | 38.8 | 47 | 14.2 | ||||
| VEGF (2) | 46 | 40 | 14 | 49 | 42 | 9 | ||||
| XPD | 44 | 46 | 10 | 34.8 | 48.4 | 16.8 | ||||
| XPA | 48.3 | 40.5 | 11.1 | 38.8 | 47 | 14.2 | ||||
| ERCC1 | 72 | 25 | 3 | 59.4 | 35.4 | 5.2 | ||||
| ERCC5 | 32 | 45 | 23 | 29.2 | 49.7 | 21.2 | ||||
| CDA |  49.5  |  39.4  |  11.1  |  —  |  —  |  —  | ||||
A indicates homozygous wild type; B, heterozygous; C, homozygous for SNP; and —, not available.
NCBI/Celera.